Juvaris goes virtual after drug, technology licensing deal

If it walks like an acquisition and quacks like an acquisition, it may be structured as a licensing deal.
Privately held Juvaris BioTherapeutics Inc. will go virtual, its CEO will focus on being an executive-in-residence at one of its venture capital backers and its vice president of research will shift to the same role at Colby Pharmaceutical Co. as Colby licenses Juvaris’ technology and a potential drug.